Cargando…

The predictive utility of circulating PCSK9 levels on diabetes mellitus

Increasing data including ours have suggested that proprotein convertase subtilisin/kexin type 9 (PCSK9), a novel regulator of cholesterol metabolism, may also play an important role in the development of type 2 diabetes mellitus (T2DM) and is associated with clinical outcomes in diabetic patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jia, Zhu, Cheng-Gang, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881449/ https://www.ncbi.nlm.nih.gov/pubmed/33581713 http://dx.doi.org/10.1186/s12933-021-01226-5

Ejemplares similares

Correlation Between Circulating PCSK9 Levels and Gestational Diabetes Mellitus in a Chinese Population
por: Wu, Yiming, et al.
Publicado: (2022)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
por: Peng, Jia, et al.
Publicado: (2022)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy
por: Kuyama, Naoto, et al.
Publicado: (2021)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
por: Lu, Fengyuan, et al.
Publicado: (2023)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus
por: Feng, Zhicai, et al.
Publicado: (2023)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

Positive correlation between plasma PCSK9 and tissue factors levels in patients with angiographically diagnosed coronary artery disease and diabetes mellitus
por: Wang, Mei, et al.
Publicado: (2016)

Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats
por: Jia, Yan-Jun, et al.
Publicado: (2014)

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
por: Reda, Ashraf, et al.
Publicado: (2020)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials
por: Cao, Ye-Xuan, et al.
Publicado: (2018)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
por: Girona, Josefa, et al.
Publicado: (2016)

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
por: Wong Chong, Emilie, et al.
Publicado: (2022)

Physical activity to reduce PCSK9 levels
por: Tirandi, Amedeo, et al.
Publicado: (2022)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
por: Guo, Wen, et al.
Publicado: (2018)

Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway
por: Laugsand, Lars E., et al.
Publicado: (2016)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

The PCSK9 Problem: Is it Predictive, Punitive, or Puzzling?
por: Pamir, Nathalie, et al.
Publicado: (2021)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

Association between the rs615563 variant of PCSK9 gene and circulating lipids and Type 2 diabetes
por: Taghizadeh Jazdani, Samira, et al.
Publicado: (2021)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

PCSK9 Is Increased in Youth With Type 1 Diabetes
por: Levenson, Amy E., et al.
Publicado: (2017)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
por: Zhang, Zhong, et al.
Publicado: (2019)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
por: Cantin, Claudette, et al.
Publicado: (2022)

Expression of a PCSK9 Gain-of-Function Mutation in C57BL/6J Mice to Facilitate Angiotensin II-Induced AAAs
por: Sawada, Hisashi, et al.
Publicado: (2022)

Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C
por: Li, Sha, et al.
Publicado: (2016)

Common and Rare PCSK9 Variants Associated with Low-Density Lipoprotein Cholesterol Levels and the Risk of Diabetes Mellitus: A Mendelian Randomization Study
por: Hsu, Lung-An, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d4bprhfa31br13ma00j1pdecbm